Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02704403




Registration number
NCT02704403
Ethics application status
Date submitted
16/02/2016
Date registered
10/03/2016
Date last updated
23/03/2022

Titles & IDs
Public title
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Secondary ID [1] 0 0
2015-005385-38
Secondary ID [2] 0 0
GFT505-315-1
Universal Trial Number (UTN)
Trial acronym
RESOLVE-IT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Nonalcoholic Steatohepatitis (NASH) With Fibrosis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Diet and Nutrition 0 0 0 0
Obesity
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: 120 mg Elafibranor - Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water

Placebo comparator: Placebo - Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis
Timepoint [1] 0 0
Measurement at 72 weeks
Primary outcome [2] 0 0
Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes
Timepoint [2] 0 0
From first randomization up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant)
Secondary outcome [1] 0 0
Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage
Timepoint [1] 0 0
Measurements at 72 weeks
Secondary outcome [2] 0 0
Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Timepoint [2] 0 0
Measurements after 72 weeks of treatment and up to study termination
Secondary outcome [3] 0 0
Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Timepoint [3] 0 0
Measurements after 72 weeks of treatment and up to study termination
Secondary outcome [4] 0 0
Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Timepoint [4] 0 0
Measurements after 72 weeks of treatment and up to study termination
Secondary outcome [5] 0 0
Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants
Timepoint [5] 0 0
Measurements after 72 weeks of treatment and up to study termination
Secondary outcome [6] 0 0
Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Timepoint [6] 0 0
Measurements after 72 weeks of treatment and up to study termination
Secondary outcome [7] 0 0
Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
Timepoint [7] 0 0
Measurements after 72 weeks of treatment and up to study termination

Eligibility
Key inclusion criteria
1. Males or females aged from 18 to 75 years inclusive at first screening visit.
2. Must provide signed written informed consent and agree to comply with the study protocol.
3. Females participating in this study must be of nonchildbearing potential or using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment, as described below:

1. Cessation of menses for at least 12 months due to ovarian failure,
2. Surgical sterilization such as bilateral oopherectomy, hysterectomy, or medically documented ovarian failure
3. If requested by local IRB regulations and/or National laws, sexual abstinence may be considered adequate (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient)
4. Using a highly effective nonhormonal method of contraception (bilateral tubal occlusion, vasectomized partner, or intra-uterine device)
5. Double contraception with barrier AND highly effective hormonal method of contraception (oral, intravaginal, or transdermal combined estrogen and progestogen hormonal contraception associated with inhibition of ovulation; oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; or intrauterine hormone-releasing system). The hormonal contraception must be started at least 1 month prior to Randomization.
4. Histological confirmation of steatohepatitis on a diagnostic liver biopsy by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period) with at least 1 in each component of the NAS score (steatosis scored 0-3, ballooning degeneration scored 0-2, and lobular inflammation scored 0-3).
5. NAS score =4.
6. Fibrosis stage of 1 or greater and below 4, according to the NASH CRN fibrosis staging system.
7. Stable dose of vitamin E, polyunsaturated fatty acids, or ursodeoxycholic acid from at least 6 months prior to diagnostic liver biopsy
8. For participants with type 2 diabetes, glycemia must be controlled. If glycemia is controlled by antidiabetic drugs, change in anti-diabetic therapy must follow these requirements:

1. No qualitative change 6 months prior to diagnostic liver biopsy up to Randomization (i.e., implementation of a new anti-diabetic therapy) for participants treated with metformin, gliptins, sulfonylureas, sodium/glucose cotransporter (SGLT) 2 inhibitors, glucagon-like peptide (GLP)-1 agonists, or insulin. Dose changes of these medications are allowed in the 6 months prior to diagnostic liver biopsy, except for GLP-1 agonists, which must remain on stable dose in the 6 months prior to diagnostic liver biopsy.
2. No implementation of GLP-1 agonists and SGLT2 inhibitors up to 72 weeks of treatment (Visit 7).

Initiation of any other antidiabetic drugs is allowed after Randomization based on treating physicians' judgment, except for glitazones which are prohibited 6 months prior to diagnostic liver biopsy until the end of treatment.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known heart failure (Grade I to IV of New York Heart Association classification).
2. History of efficient bariatric surgery within 5 years prior to screening.
3. Uncontrolled hypertension during the Screening Period despite optimal antihypertensive therapy
4. Type 1 diabetes participants .
5. Participants with decompensated diabetes (HbA1c>9%).
6. Participants with a history of clinically significant acute cardiac event within 6 months prior to screening
7. Weight loss of more than 5% within 6 months prior to randomization
8. Compensated and decompensated cirrhosis
9. Current or recent history (<5 years) of significant alcohol consumption
10. Pregnant or lactating females or females planning to become pregnant during the study period.
11. Other well documented causes of chronic liver disease according to standard diagnostic procedures
12. Participants with previous exposure to Elafibranor
13. Prohibited concomitant medication
14. Any medical conditions that may diminish life expectancy to less than 2 years including known cancers.
15. Evidence of any other unstable or untreated clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease.
16. Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
17. Participants with biological criteria exclusion as per effective protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/10/2020
Sample size
Target
Accrual to date
Final
2157
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [3] 0 0
Monash Medical Centre Clayton - Clayton
Recruitment hospital [4] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [5] 0 0
St. Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [6] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [7] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [8] 0 0
The St George Hospital - Kogarah
Recruitment hospital [9] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [10] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [11] 0 0
Sir Charles Gairdner Hospital (SCGH) - Nedlands
Recruitment hospital [12] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
2139 - Concord
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
2747 - Kingswood
Recruitment postcode(s) [8] 0 0
2217 - Kogarah
Recruitment postcode(s) [9] 0 0
3004 - Melbourne
Recruitment postcode(s) [10] 0 0
6150 - Murdoch
Recruitment postcode(s) [11] 0 0
6009 - Nedlands
Recruitment postcode(s) [12] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Hawaii
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Mississippi
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
Rhode Island
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Utah
Country [31] 0 0
United States of America
State/province [31] 0 0
Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
Argentina
State/province [33] 0 0
Buenos Aires
Country [34] 0 0
Argentina
State/province [34] 0 0
La Plata
Country [35] 0 0
Argentina
State/province [35] 0 0
Pilar
Country [36] 0 0
Argentina
State/province [36] 0 0
Ramos Mejía
Country [37] 0 0
Argentina
State/province [37] 0 0
Rosario
Country [38] 0 0
Argentina
State/province [38] 0 0
Salta
Country [39] 0 0
Belgium
State/province [39] 0 0
Bruxelles
Country [40] 0 0
Belgium
State/province [40] 0 0
Edegem
Country [41] 0 0
Belgium
State/province [41] 0 0
Gent
Country [42] 0 0
Belgium
State/province [42] 0 0
Leuven
Country [43] 0 0
Belgium
State/province [43] 0 0
Tournai
Country [44] 0 0
Canada
State/province [44] 0 0
British Columbia
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
Canada
State/province [47] 0 0
Calgary, AB
Country [48] 0 0
Canada
State/province [48] 0 0
Halifax
Country [49] 0 0
Canada
State/province [49] 0 0
Montreal
Country [50] 0 0
Canada
State/province [50] 0 0
Winnipeg, MB
Country [51] 0 0
Chile
State/province [51] 0 0
La Serena
Country [52] 0 0
Chile
State/province [52] 0 0
Los Ángeles
Country [53] 0 0
Chile
State/province [53] 0 0
Santiago
Country [54] 0 0
Chile
State/province [54] 0 0
Vina Del Mar
Country [55] 0 0
Colombia
State/province [55] 0 0
Bogota D.C
Country [56] 0 0
Colombia
State/province [56] 0 0
Bogotá
Country [57] 0 0
Colombia
State/province [57] 0 0
Cali
Country [58] 0 0
Colombia
State/province [58] 0 0
Medellin
Country [59] 0 0
Colombia
State/province [59] 0 0
Medellín
Country [60] 0 0
Czechia
State/province [60] 0 0
Brno
Country [61] 0 0
Czechia
State/province [61] 0 0
Plzen
Country [62] 0 0
Czechia
State/province [62] 0 0
Praha 2
Country [63] 0 0
Denmark
State/province [63] 0 0
Aarhus
Country [64] 0 0
Finland
State/province [64] 0 0
Helsinki
Country [65] 0 0
France
State/province [65] 0 0
Amiens
Country [66] 0 0
France
State/province [66] 0 0
Angers
Country [67] 0 0
France
State/province [67] 0 0
Clamart
Country [68] 0 0
France
State/province [68] 0 0
Clichy
Country [69] 0 0
France
State/province [69] 0 0
Créteil
Country [70] 0 0
France
State/province [70] 0 0
Limoges
Country [71] 0 0
France
State/province [71] 0 0
Lyon
Country [72] 0 0
France
State/province [72] 0 0
Marseille
Country [73] 0 0
France
State/province [73] 0 0
Montpellier
Country [74] 0 0
France
State/province [74] 0 0
Nantes
Country [75] 0 0
France
State/province [75] 0 0
Nice
Country [76] 0 0
France
State/province [76] 0 0
Paris
Country [77] 0 0
France
State/province [77] 0 0
Pessac
Country [78] 0 0
France
State/province [78] 0 0
Toulouse
Country [79] 0 0
France
State/province [79] 0 0
Vandoeuvre Les Nancy
Country [80] 0 0
France
State/province [80] 0 0
Villejuif
Country [81] 0 0
Germany
State/province [81] 0 0
Northwest
Country [82] 0 0
Germany
State/province [82] 0 0
Aachen
Country [83] 0 0
Germany
State/province [83] 0 0
Berlin
Country [84] 0 0
Germany
State/province [84] 0 0
Bonn
Country [85] 0 0
Germany
State/province [85] 0 0
Essen
Country [86] 0 0
Germany
State/province [86] 0 0
Frankfurt
Country [87] 0 0
Germany
State/province [87] 0 0
Freiburg
Country [88] 0 0
Germany
State/province [88] 0 0
Hamburg
Country [89] 0 0
Germany
State/province [89] 0 0
Hannover
Country [90] 0 0
Germany
State/province [90] 0 0
Heidelberg
Country [91] 0 0
Germany
State/province [91] 0 0
Köln
Country [92] 0 0
Germany
State/province [92] 0 0
Leipzig
Country [93] 0 0
Germany
State/province [93] 0 0
Magdeburg
Country [94] 0 0
Germany
State/province [94] 0 0
Mainz
Country [95] 0 0
Germany
State/province [95] 0 0
Würzburg
Country [96] 0 0
Italy
State/province [96] 0 0
Bologna
Country [97] 0 0
Italy
State/province [97] 0 0
Milano
Country [98] 0 0
Italy
State/province [98] 0 0
Napoli
Country [99] 0 0
Italy
State/province [99] 0 0
Palermo
Country [100] 0 0
Italy
State/province [100] 0 0
Roma
Country [101] 0 0
Italy
State/province [101] 0 0
San Giovanni Rotondo
Country [102] 0 0
Italy
State/province [102] 0 0
Torino
Country [103] 0 0
Mexico
State/province [103] 0 0
DIF
Country [104] 0 0
Mexico
State/province [104] 0 0
Acapulco
Country [105] 0 0
Mexico
State/province [105] 0 0
Guadalajara
Country [106] 0 0
Mexico
State/province [106] 0 0
Mexico City
Country [107] 0 0
Mexico
State/province [107] 0 0
Monterrey
Country [108] 0 0
Netherlands
State/province [108] 0 0
Amsterdam
Country [109] 0 0
Netherlands
State/province [109] 0 0
Maastricht
Country [110] 0 0
Netherlands
State/province [110] 0 0
Nijmegen
Country [111] 0 0
Portugal
State/province [111] 0 0
Coimbra
Country [112] 0 0
Portugal
State/province [112] 0 0
Lisboa
Country [113] 0 0
Portugal
State/province [113] 0 0
Porto
Country [114] 0 0
Portugal
State/province [114] 0 0
Vila Real
Country [115] 0 0
Puerto Rico
State/province [115] 0 0
Rio Grande
Country [116] 0 0
Puerto Rico
State/province [116] 0 0
San Juan
Country [117] 0 0
Romania
State/province [117] 0 0
Bucharest
Country [118] 0 0
Romania
State/province [118] 0 0
Timisoara
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Moscow
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Saint Petersburg
Country [121] 0 0
Russian Federation
State/province [121] 0 0
St. Petersburg
Country [122] 0 0
South Africa
State/province [122] 0 0
Cape Town
Country [123] 0 0
South Africa
State/province [123] 0 0
Port Elizabeth
Country [124] 0 0
Spain
State/province [124] 0 0
Barcelona
Country [125] 0 0
Spain
State/province [125] 0 0
Madrid
Country [126] 0 0
Spain
State/province [126] 0 0
Majadahonda
Country [127] 0 0
Spain
State/province [127] 0 0
Málaga
Country [128] 0 0
Spain
State/province [128] 0 0
Pontevedra
Country [129] 0 0
Spain
State/province [129] 0 0
Santander
Country [130] 0 0
Spain
State/province [130] 0 0
Sevilla
Country [131] 0 0
Sweden
State/province [131] 0 0
Stockholm
Country [132] 0 0
Switzerland
State/province [132] 0 0
Bern
Country [133] 0 0
Switzerland
State/province [133] 0 0
Lausanne
Country [134] 0 0
Switzerland
State/province [134] 0 0
Saint Gallen
Country [135] 0 0
Switzerland
State/province [135] 0 0
Zurich
Country [136] 0 0
Turkey
State/province [136] 0 0
Ankara
Country [137] 0 0
Turkey
State/province [137] 0 0
Fatih
Country [138] 0 0
Turkey
State/province [138] 0 0
Istanbul
Country [139] 0 0
Turkey
State/province [139] 0 0
Izmir
Country [140] 0 0
Turkey
State/province [140] 0 0
Pendik
Country [141] 0 0
Turkey
State/province [141] 0 0
Çapa
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Birmingham
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Cambridge
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Frimley
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Hull
Country [146] 0 0
United Kingdom
State/province [146] 0 0
London
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Newcastle upon Tyne
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Nottingham
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Plymouth
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Portsmouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Genfit
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Trial website
https://clinicaltrials.gov/study/NCT02704403
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Carol Addy, MD MMSc
Address 0 0
Genfit
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02704403